January 26, 2012
Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
A*STAR scholar Ms Christine Cheung first author of team paper published this month in Nature Biotechnology*
Singapore, Jan 26, 2012 - (ACN Newswire) - A Cambridge University research team has for the first time discovered a method of generating different types of vascular smooth muscle cells (SMCs) - the cells which make up the walls of blood vessels - using cells from patients' skin. This work could lead to new treatments and better screening for cardiovascular disease.
Cardiovascular disease is the leading cause of death in the world**. These deaths are mainly caused by the hardening and subsequent blockage of blood vessels due to the accumulation of fatty materials, a condition called atherosclerosis. As not all patients are suitable for conventional stenting or bypass treatment, an option in the future may be to grow new blood vessels to bypass their own blocked vessels.
The team from Cambridge worked with embryonic stem cells and reprogrammed skin cells, collectively known as human pluripotent stem cells (hPSCs), which have the potential to form any cell type in the body. They discovered a method of creating all the majorvascular smooth muscle cells in high purity using hPSCs which can also be easily scaled up for production of clinical-grade SMCs. This is the first time that such a system has been developed and will open the door for comparative studies on differentsubtypes of SMCs to be carried out, which are otherwise extremely difficult to obtain from patients.
The scientists created three subtypes of SMCs from different embryonic tissues which they reproduced in the culture dish and showed that the various SMC subtypes responded differently when exposed to substances that cause vascular diseases. They concluded that differences in the embryonic origin play a role in their susceptibility to diseases and may play a part in determining where and whencommon vascular diseases such as aortic aneurysms or atherosclerosis develop.
Dr Alan Colman, Principle Investigator of the Institute of Medical Biology under A*STAR and Executive Director of the Singapore Stem Cell Consortium, said, "This is a major advance in vascular disease modelling using patient-derived stem cells. The development of robust methods to make multiple, distinct smooth muscle subtypes provides tools for scientists to model and understand a greater range of vascular diseasesin a culture dish than was previously available. It is a significant stride forward in being able to construct new blood vessels which will benefit a whole range of patients including those with cardiovascular diseases, renal failure and genetic disorders such as Marfans Syndrome that affect the normal function of their blood vessels."
Dr Lim Khiang Wee, Executive Director of the A*STAR Graduate Academy (A*GA), said, "Christine's work reflects the calibre of our scholars - they do excellentresearch and grow into scientists who will contribute to Singapore when they return."
Ms Christine Cheung is a National Science Scholarship (NSS) scholar and is doing her final year PhD studies at Cambridge University (UK). The NSS scholarship isone of the programmes offered by A*GA, to attract and develop outstanding young talent passionate about research who will spearhead Singapore's drive to becoming Asian's Innovation Capital.
* The paper "Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility" was published on Nature Biotechnology's website on 15 January. Ms Christine Cheung is funded by a National Science Scholarship from the A*STAR (Agency for Science, Technology and Research, Singapore). The other authors are Dr Andreia S Bernardo, Dr Matthew W B Trotter, Prof Roger A Pedersen & Dr Sanjay Sinha (Christine's PhD supervisor). Additional funding was provided by the Wellcome Trust and the Medical Research Council. http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.2107.html
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners. For more information about A*STAR, please visit www.a-star.edu.sg.
Ms Ong Siok Ming Senior Officer, Corporate Communications Agency for Science, Technology and Research Tel: +65 6826 6254 Email: [email protected]>
Copyright 2012 ACN Newswire. All rights reserved.